{"name":"OrsoBio, Inc","slug":"orsobio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"TLC-1180 Oral Solution","genericName":"TLC-1180 Oral Solution","slug":"tlc-1180-oral-solution","indication":"Other","status":"phase_1"},{"name":"TLC-2716 Dose 1","genericName":"TLC-2716 Dose 1","slug":"tlc-2716-dose-1","indication":"Other","status":"phase_2"},{"name":"TLC-3595 Dose 1","genericName":"TLC-3595 Dose 1","slug":"tlc-3595-dose-1","indication":"Other","status":"phase_2"},{"name":"TLC-6740 Oral Solution","genericName":"TLC-6740 Oral Solution","slug":"tlc-6740-oral-solution","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TLC-1180 Oral Solution","genericName":"TLC-1180 Oral Solution","slug":"tlc-1180-oral-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TLC-2716 Dose 1","genericName":"TLC-2716 Dose 1","slug":"tlc-2716-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TLC-3595 Dose 1","genericName":"TLC-3595 Dose 1","slug":"tlc-3595-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TLC-6740 Oral Solution","genericName":"TLC-6740 Oral Solution","slug":"tlc-6740-oral-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQX1dfSFBFWUwtT0lOZF9uV0w5MlFfQmVhSW9adnRnaktyUzZZUTVJeTdzZzNPZ1puR0hZWk1WYnVWRVM0MTlPOE9pOTBCX1BES0FzYlpoSE93MUZqSi05dV9HV3haWU53OUJBVXcxdVJpc2hqNU5DM213RlNudmlkRlREeTFsOC13M2Y1cVl4cXlVb2JfZkNZUXhodm1WdnFKaFZRNlV5MTBfVGd4T0ZCUEw2SkY?oc=5","date":"2026-02-10","type":"trial","source":"Fierce Biotech","summary":"OrsoBio hits target in midstage study for metabolic conditions but stays silent on details - Fierce Biotech","headline":"OrsoBio hits target in midstage study for metabolic conditions but stays silent on details","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPVWdINUl5Mk81LTJDTFBmSGoyU01GNjBiUlJJeFRnWDhYVEg4VzNrZ2tFdVM4Z1RPZHB0NE5nQ2otQ1lscHJtaV8ycFVTdGdtcE9vZnA1VUZxVnpvblprd2ZsLXhSQVNrbWFGcXpaX1NFWWtaNDdtS2dRMU51cWRUaHhTbEw5Rm5uZDhodHJfUEJIU2U1eVR5TkhoOHZwamR2TDdnb2x5N3JodFp5N29QTg?oc=5","date":"2026-02-10","type":"trial","source":"The Business Journals","summary":"Former Gilead execs' startup targets fresh funding based on fat-fighting drug's study results - The Business Journals","headline":"Former Gilead execs' startup targets fresh funding based on fat-fighting drug's study results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPUTlCR0I0OUxOanBXZmpCQkdaS0UxVkRHeXBnRjFwNGdRczh2TFdOcnp3NE9xT1JfdlBRcHA5S0F1b0NWZTI2YkVIN0U0Y0ZSeXFwNThWOGlwbXhwZk1FLVc5VGRpaHFSa3I0Um02Q0JMeDBDZ0xLeEg0bkY3X2c2dUxXdUFEal9Fc2o5bVlGMVpMSERaaV93SlBlQnlzRFA1SnZmNjVTaEg5LUFrcWdIaFhaN2hCbHdraHBOTDBwd2Q1WW9BS0t5elVfRlN1WTlLQmt0ZmRCMlhrc2ZJeHRGTndyQVRiWkhna3VzRFAzU1lydw?oc=5","date":"2025-11-05","type":"trial","source":"BioSpace","summary":"OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025 - BioSpace","headline":"OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 202","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNZzd0TGZvZ1A3RmVQdmpvNWFNOUpWS1MtRXhWbkxQTW1SMDl0WUNYamc4Q0ZvcjRGTjBqbjRFN3p2STUxaHB3Qno1QnFXdlFjZmxicWY1MGRJWWZ3b2t0XzBuSmQyRUt4REpob1JtVUxwUnRzYnJpMENTUWFOZndWSzRpbjNHSkNQY2N4OHdGVjI2ZWNFT2hRRjk1TUJveEpyMi16dTJZR2poLVd3TTZ1eg?oc=5","date":"2025-07-31","type":"pipeline","source":"Pharmaceutical Technology","summary":"Targeting energy expenditure: the next wave of obesity drugs - Pharmaceutical Technology","headline":"Targeting energy expenditure: the next wave of obesity drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNbzVTTWhUaV9FTlh4TzJJRUNOWDBzTDdYNUJROXFwY05fY2ZDUkFONHA2RkNjeWRpTXdTZ2J1OGhwYWNjbms2NklfOE9Wa3NmMmdkOWh1d2J0TXFSMzdtN2txaWU3SW1wbjliQk83b1VfZnptMkV4eS1jSU5zMlItZnoyYzNHZV82cEs0?oc=5","date":"2024-09-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"OrsoBio secures funds to develop obesity treatment portfolio - Pharmaceutical Technology","headline":"OrsoBio secures funds to develop obesity treatment portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPYjcyNFJNb2QyRm5ZbXZ0Vm1CbmhjWVBDRDAzRHlZNnhLcldVdk82cXRteHN6OW9jZlo5ZkNnLS1mb0otaG5YbWkwRVlNMnlWbkRzUE9TVUk5eHJxYTNVSnlqSThfb1k4bjVRcVhYUHJXUDViS19INWZMeHhaYWZrTlZjNWttalNORF9Wekp0MzlIeVU2NFRRR2xGRFRuX0ZGcGc0RXJfWno3dGVkbTJ2MGV2QjJ0VGppNW9OdTMwMC1oVHhmc3dGSnZfVmMwQ3RybzE1NThDaWtIUTFpZVRUR2R4MXdCMVIxa3c?oc=5","date":"2024-02-02","type":"pipeline","source":"drugdiscoverytrends.com","summary":"OrsoBio explores mitochondrial angle on metabolic disorders - drugdiscoverytrends.com","headline":"OrsoBio explores mitochondrial angle on metabolic disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOV09pSFJQY05tbGpSRzhrTzRLZDJkZ1pvWkM4Y2xsamNtazNCZ1hOOElvMzlXOFVhdzdBams1bE5iVUNyVkxqZWtVUC0wZnVlREh4UDlfRDR6V0tEUHg3NFF6ZHBqWmhwZHZlMFRLX3RBTzlTZ2VhVWNYdy1HcmEzcmIwUTVSaXlKank4aUs5Nko0U2VwdURpTXF2WUNPdUwycExaRHZHZGtydERvcjZ3?oc=5","date":"2023-11-20","type":"pipeline","source":"The Business Journals","summary":"With rise of GLP-1 drugs, Peninsula biopharma targets another approach to diabetes and obesity - The Business Journals","headline":"With rise of GLP-1 drugs, Peninsula biopharma targets another approach to diabetes and obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNRDhJN2tHVTlZTTBHWjFIX1p1alFsbmhndWdTQVRWeGt6YTV0NkFlcExKejRpTV9XWkxrcVlSdnUxQnZZUk4tSTY3bUQtMkszUVdUN2kwVG52LVY1am9TUWRxa0JJaVVESGNrSGt5bTV5VENWUlJyMktjUlh3YTVSdTU2aUdoR1RGaTdOZFg0Zkw3RTJHdUE?oc=5","date":"2023-11-07","type":"deal","source":"BioPharma Dive","summary":"An obesity drug biotech gets buy-in from Eli Lilly, venture firms - BioPharma Dive","headline":"An obesity drug biotech gets buy-in from Eli Lilly, venture firms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOTmtjTWpDM04xeUpfdkhRaDVlODV3LTRCR2lDUFlYOW0xSnEtS1AzRWhpeW5uZ2JMSlFmS1ZFMnZVM2s4QjhEakxkU0owcndXSkl5VFVFbEhOd2hqNURlU1puZHRKRy1kWU8waU1tZW5ZZTlydXZQM3FVYnp3c0FDR1NtemdwQjV3UHJKcFAyQ0FTTTNsYm94blczdVAzRi1KeTF1Rzc5RFVfSV8wTUNEbg?oc=5","date":"2022-11-23","type":"pipeline","source":"BioWorld News","summary":"LXR inverse agonist TLC-2716 reduces lipogenesis in preclinical models - BioWorld News","headline":"LXR inverse agonist TLC-2716 reduces lipogenesis in preclinical models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOblZCaXh4WEFWaHpmWHFpOHB4LUpBZUtiY2ZRNGpYNkJJVEVvUThQQU9vNXAtdmRkNlJxQ0xHel8ybmxZWmxQZERBWjNKZk5hWnJ5X2tkWjNmRnBiUl9VVzg1N1BZNkloMUhyUzZfT25FeFQ2R3ZjN2dES25SQURkR1JleWFXb1ppTDFXYWpTUEw4N0tQVkJpOEotN1ZuYllyTjJvbEtNcVE3VXZhdlM1MDNQWGp1Zm02?oc=5","date":"2022-11-02","type":"pipeline","source":"Fierce Biotech","summary":"5 press releases, one biotech: Gilead alums debut OrsoBio with frenzy of metabolic programs - Fierce Biotech","headline":"5 press releases, one biotech: Gilead alums debut OrsoBio with frenzy of metabolic programs","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_2":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}